Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections

CompletedOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 1, 2021

Conditions
Disseminated Intravascular CoagulationCritical IllnessSars-CoV2Viral InfectionCoagulation Disorder, BloodCovid19
Interventions
DIAGNOSTIC_TEST

Thrombin Generation Assay (TGA)

"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."

DIAGNOSTIC_TEST

Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)

Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.

Trial Locations (1)

1090

Medical University Vienna, Vienna

All Listed Sponsors
collaborator

Medical Scientific Fund of the Mayor of Vienna

OTHER

lead

Medical University of Vienna

OTHER

NCT04356144 - Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections | Biotech Hunter | Biotech Hunter